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Chronic HCV infection can lead to cirrhosis and is associated with increased mortality.
Interleukin (IL)-10-producing B cells (B10 cells) are regulatory cells that suppress cellu-
lar immune responses. Here, we aimed to determine whether HCV induces B10 cells
and assess the roles of the B10 cells during HCV infection. HCV-induced B10 cells were
enriched in CD19hi and CD1dhiCD5+ cell populations. HCV predominantly triggered the
TLR2-MyD88-NF-κB and AP-1 signaling pathways to drive IL-10 production by B cells. In
a humanized murine model of persistent HCV infection, to neutralize IL-10 produced by
B10 cells, mice were treated with pcCD19scFv-IL-10R, which contains the genes coding
the anti-CD19 single-chain variable fragment (CD19scFv) and the extracellular domain
of IL-10 receptor alpha chain (sIL-10Ra). This treatment resulted in significant reduc-
tion of B10 cells in spleen and liver, increase of cytotoxic CD8+ T-cell responses against
HCV, and low viral loads in infected humanized mice. Our results indicate that target-
ing B10 cells via neutralization of IL-10 may offer a novel strategy to enhance anti-HCV
immunotherapy.
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 Additional supporting information may be found online in the Supporting Information sectionat the end of the article.
Introduction
HCV is a blood-borne virus characterized by high chronic infection
rates (over 80%) [1]. Although the use of direct-acting antivirals
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significantly improved the outcome of HCV treatment, these costly
therapeutic cocktails already face issues such as viral mutation
and reinfection following therapy [2]. Additionally, the failure
to successfully manage chronic HCV infection in specific patient
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populations, and the lack of an effective vaccine against HCV rep-
resent major hurdles to control this global infection [3, 4]. There-
fore, new insights into the pathogenesis of HCV and the virus-host
response are needed to overcome these challenges.
HCV has evolved multiple strategies to evade host immunity
and develop chronic infection in humans. Increased levels of IL-10
producing B cells (B10 cells) have been found in chronic hepatitis
C (CHC) patients and is correlated with poor virus elimination,
indicating that B10 cells are involved in the progress of chronic
HCV infection [5]. B10 cells, a subset of regulatory B cells (Bregs),
inhibit various immune responses through their IL-10 production
[6]. These cells reportedly participate in viral immune evasion
during infection with human immunodeficiency and hepatitis B
viruses [7, 8]. However, little is known about the role of B10 cells
in HCV infection.
A single-chain variable fragment (scFv) is recombinant mono-
valent Ab lacking the constant part of both the heavy and light
chains [9, 10]. We recently employed the recombinant plasmid
pcCD19scFv-IL10R, which contains the genes for anti-CD19 scFv
(CD19scFv) and extracellular domain of IL-10 receptor alpha
chain (sIL-10Ra) to specifically inhibit B cell-secreted IL-10 as
well as the regulatory activity of B10 cells in a murine model [9].
In the present study, we present a novel strategy to potentially
enhance anti-HCV immunotherapy via the neutralization of IL-10
secretion by B cells.
Results
HCV induces B10 cells in human PBMCs in vitro
Increased B10 cell levels have been found in CHC patients [5];
therefore, we measured the frequency of B10 cells in human
PBMCs after stimulation with cell culture-derived HCV (HCVcc).
As shown in Fig. 1A and B, stimulation with HCV significantly
increased the percentage of IL-10+CD19+ B cells in PBMCs com-
pared with the control medium group (3.15 ± 1.48 % vs. 0.52 ±
0.35%). The histograms overlays showed that the whole peak was
shifted up in HCV group, indicating that not only a subset of B
cells upregulated IL-10 after exposure to HCV, but probably most
of B cells (Fig. 1B). Blood B10 cells from adult humans report-
edly show heightened levels of CD19 [6]; therefore, we analyzed
the distribution of HCVcc-induced B10 cells in CD19lo and CD19hi
cell populations. As shown in Fig. 1C and D, markedly higher fre-
quencies of HCVcc-induced B10 cells were observed in CD19hi B
cells compared with CD19lo B cells. These results indicated that
increased B10 cell levels might be associated with HCV infection.
Murine B10 cells are enriched in CD19hi and CD1dhi
CD5+ populations after HCV stimulation in vitro
To investigate whether HCV directly induces B cells to produce IL-
10, purified murine B cells were stimulated with HCVcc in vitro.
As shown in Fig. 2A, IL-10 production by CD19+ B cells signifi-
cantly increased after HCVcc stimulation. The frequency of B10
cells in CD19+ B cells persistently increased upon stimulation for
an extended period of time (48-72 h) or with increased concentra-
tions of HCVcc (5 × 105 to 5 × 106 RNA copies/mL; Fig. 2B and C
and Supporting information Fig. 1A and B). These results demon-
strated that HCVcc directly induces production of murine B10
cells in vitro. Consistent with the distribution of HCVcc-induced
human B10 cells, murine B10 cell frequency was much higher
in the CD19hi population than in the CD19lo population after
HCVcc stimulation (Fig. 2D). High B10 cell percentages were also
found in CD1dhiCD5+ after stimulation with HCVcc (Fig. 2E).
CD1dhiCD5+ B cells contains marginal zone (MZ) B and B1 B cells
[11], which can be rapidly recruited into early adaptive immune
responses in a T cell-independent manner.
HCV drives IL-10 production by B cells via TLR2-
MyD88-NF-κB and AP-1 signaling pathways in vitro
TLR2 and TLR4 signaling in immune cells can be triggered by
HCV [12, 13], and is reportedly involved in IL-10 production in
B cells [14, 15]. Therefore, we investigated whether TLR2 and
TLR4 were involved in HCV-induced IL-10 production by B cells.
IL-10 levels decreased after HCV stimulation by approximately
70 and 50% in TLR2−/- and TLR4−/- groups, respectively, com-
pared with WT group (Fig. 3A). These results indicated that HCV-
induced IL-10 production by B cells was both TLR2 and TLR4
dependent, predominantly via the TLR2 signaling pathway.
We then explore the adapter proteins and transcription fac-
tors downstream of TLR2 that significantly contributed to IL-
10 production. As shown in Fig. 3B, inhibition of MyD88, P38,
PI3K, NF-κB, and AP1 significantly decreased IL-10 production by
HCVcc-treated B cells. Immunoblot analysis revealed that PI3K
and its downstream target AKT were highly phosphorylated after
15 min of HCV stimulation (Fig. 3C and Supporting information
Fig. 2A). The peaks of NF-κB (p-P65) and AP-1 (p-c-fos) acti-
vation were obtained after 15 min and 2 h of HCV stimulation,
respectively (Fig. 3C and Supporting information Fig. 2A). Com-
pared with WT B + HCVcc group, HCV-induced activation of PI3K,
AKT, NF-kB, and AP-1 in B cells was significantly reduced in the
TLR2−/− group, (Fig. 3D and Supporting information Fig. 2B) or
in the presence of MyD88 inhibitor (Fig. 3E and Supporting infor-
mation Fig. 2C). These results further demonstrated that HCVcc
triggers the TLR2-MyD88-NF-κB and AP-1 signaling pathways in
B cells.
Neutralization of IL-10 secretion by B cells reduces
viral loads during persistent HCV infection
Transgenic mice harboring both human CD81 and OCLN
(occludin) genes have been reportedly used as an animal model
of persistent HCV infection at a chronicity rate comparable to
humans [16, 17]. Human scavenger receptor class B type I (SRBI)
and claudin1 (CLDN1) are reportedly both required for HCV entry
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Figure 1. HCVcc induces B10 cells in human PBMC in vitro. (A) and (B) Human PBMCs were stimulated with HCVcc for 48 h, B10 cells were
determined by flow cytometry. (A) Pooled data of the frequency of B10 cells . **p < 0.01, ANOVA with Neuman–Keuls posthoc test. (B) Representative
flow plots. (C) and (D) HCV-induced B10 cells were enriched in CD19hi B cells. (C) Pooled data of the frequency of B10 cells. ***p < 0.001, ANOVA
with Neuman–Keuls posthoc test. (D) Representative flow plots. Data in (A) and (C) are shown as the mean ± SD (n = 14 donors). The data are
summary of three independent experiments using n = 14 donors in total.
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Figure 2. HCVcc induces murine B10 cells in vitro. (A) IL-10 production by B cells after HCVcc stimulation. Murine B cells were stimulated with
HCVcc (1 × 106 RNA copies/mL) or LPS (10 μg/mL) for 0, 18, 48, and 72 h. IL-10 production in cell culture supernatant was detected by ELISA. (B)
Murine B cells were stimulated with HCVcc (1 × 106 RNA copies/mL) for the indicated time periods. B10 cell frequencies were determined by flow
cytometry. (C) B cells were stimulated with various concentrations of HCVcc for 48 h, B10 cells were determined by flow cytometry. Data in (A)
to (C) are shown as the mean ± SD (n = 3 mice per experiment). **p < 0.01, ***p < 0.001, ****p < 0.0001, ANOVA with Neuman–Keuls posthoc test.
(D) and (E) B cells were stimulated with HCVcc (1 × 106 RNA copies/mL) for 48 h. B10 cell percentages were determined in CD19hi/lo B cells or
CD1dhi/loCD5+/− B cells. All data are representative of at least three independent experiments with similar results.
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Figure 3. HCVcc induces IL-10 production by B cells via TLR2-MyD88-NF-κB and AP-1 signaling pathway. (A) Murine CD19+ B cells were isolated
from splenocytes of TLR2−/−, TLR4−/− and WT mice. The B cells were stimulated with HCVcc for 48 h. The IL-10 concentrations in the supernatants
were detected by ELISA. (B) Murine WT B cells were treated with MyD88, PI3K, P38, NF-κB, and AP1 inhibitor for 1 h prior to stimulation with
HCVcc. After 48 h of HCVcc stimulation, the concentration of IL-10 in culture supernatant was determined by ELISA. (C) WT B cells were stimulated
with HCVcc for the indicated time periods. The phosphorylation of PI3K, AKT, NF-κB, and AP1 were determined by immunoblot analysis. (D) WT
B cells and TLR2−/- B cells were stimulated with HCVcc for the indicated time periods. The phosphorylation of PI3K, AKT, NF-κB, and AP1 were
determined by immunoblot analysis. (E) WT B cells were stimulated with HCVcc in the presence of MyD88 inhibitor for the indicated time periods.
The phosphorylation of PI3K, AKT, NF-κB, and AP1 were then determined by immunoblot analysis. β-actin was used as a loading control (C-E).
Data in (A)–(E) are shown as the mean ± SD (n = 3 mice per experiment). **p < 0.01, ***p < 0.001, ANOVA with Neuman–Keuls posthoc test. All Data
are from a single experiment representative of at least three independent experiments.
into hepatocytes [18–20]. In the present study, ICRTg4R+ human-
ized mice that express human CD81, OCLN, SRBI, and CLDN1
molecules in the liver were used as a persistent HCV infection
mode. As shown in Supporting information Fig. 3A and B, 1345 ±
134 HCV RNA copies per milliliters in serum, and HCV NS3 and
core proteins in the liver tissues were detected in the ICRTg4R+ mice
60 days postinfection (dpi), demonstrating that HCV established
persistent infection in the ICRTg4R+ mice.
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In the present study, we used pcCD19scFv-IL-10R to investi-
gate the role of B10 cells during the HCV infection in vivo. On day
0, ICRTg4R+ mice were infected (i.v.) with HCVcc. pcCD19scFv-
IL-10R and pcIL-10R were injected (i.m.) into the mice weekly
(Fig. 4A). Soluble CD19scFv-IL-10R and sIL-10Ra proteins were
detected in the serum 5 days postplasmid injection (Supporting
information Fig. 4A). On day 60, IL-10 levels were significantly
decreased in the pcCD19scFv, pcCD19scFv-IL-10R, and pcIL-10R
groups, indicating that CD19scFv, CD19scFv-IL-10R, and sIL-10Ra
proteins effectively decreased serum IL-10 in mice (Fig. 4B). Treat-
ment with pcCD19scFv-IL-10R and pcIL-10R also significantly
decreased the HCV load in the mice compared with the pcDNA
group, but treatment with pcCD19scFv slightly reduced the HCV
load in the mice (Fig. 4C).
Consistent with decreased HCV loads, decreased NS3 expres-
sion was observed in liver tissues of pcCD19scFv-IL-10R and pcIL-
10R groups (Fig. 4D and Supporting information Fig. 4B). Treat-
ment with pcCD19scFv-IL-10R and pcIL-10R markedly reduced
hepatocellular swelling and periportal sinusoidal fibrosis (Fig. 4E
and Supporting information Fig. 4C). Together, these results
demonstrated that pcCD19scFv-IL-10R and pcIL-10R treatments
inhibit HCV infection in vivo.
Blocking IL-10 production by B cells reduces B10 cells
in HCV-infected mice
To address the effects of pcCD19scFv-IL-10R treatment on B10
in vivo, we examined B10 cells in HCV-infected mice. Both
pcCD19scFv-IL-10R and pcIL-10R treatments significantly reduced
the frequency of splenic B10 cells (Fig. 5A and Supporting infor-
mation Fig. 5A). In immunofluorescence assay, IL-10+CD19+ B
cells were found in CD19+ B cells accumulated in the liver tissues
of HCV and pcDNA + HCV groups, while reduced B10 cells were
observed in the liver tissues of pcCD19scFv-IL-10R and pcIL-10R
groups (Fig. 5B). These results indicated that pcCD19scFv-IL-10R
treatment might hinder B10 cell function via neutralization of IL-
10 and reduction of HCV-induced B10 cells (Fig. 5A and B). All
mice (including the pcDNA group) subjected to plasmid injection
showed a decreased frequency of splenic Tregs (Fig. 5C and Sup-
porting information Fig. 5B).
Blockage of IL-10 secretion by B10 cells enhances
CD8+ T cytotoxicity in HCV-infected mice
To further evaluate the anti-HCV immune effect in mice after
pcCD19scFv-IL-10R treatment, we determined the frequencies of
Th1, Th2, and Th17 cells by detecting IFN-γ, IL-4, and IL-17A,
respectively (Fig. 6A–C and Supporting information Fig. 6A-C).
No obvious differences were observed in frequencies of Th1, Th2,
and Th17 cells among the groups, indicating that neutralizing
B cell-produced IL-10 nearly had no influence on Th polarization
during HCV infection. However, the percentages of perforin+CD8+
T cells from the spleen and liver in pcCD19scFv-IL-10R and
Figure 4. Neutralization of IL-10 secretion by B cells reduces viral loads
during persistent HCV infection in humanized mice (A) Schematic dia-
gram. On day 0, the ICRTg4R+ mice were infected with HCVcc (1 × 107
RNA copies/mouse, i.v.) and injected with pcCD19scFv-IL-10R, pcIL-10R,
or pCD19scFv once a week. On day 60, the viral loads in the mice and
anti-HCV immune response were assessed. (B) Serum IL-10 concentra-
tions were determined by ELISA 60 dpi. (C) Serum HCV RNA copies were
detected by RT-qPCR based on the relative expression of GAPDH. (D) IHC
assay for NS3 detection in liver tissues (200 ×). Scale bars, 100 μm. (E)
Liver specimen was stained with HE (200 ×). Scale bars, 100 μm. Data
in (B) and (C) are shown as the mean ± SD (n = 6 mice per experiment).
***p < 0.001, ANOVA with Neuman–Keuls posthoc test. (D) and (E) Rep-
resentative of three mice per experiment. All data are representative of
at least three independent experiments with similar results.
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Figure 5. Blocking IL-10 production by B cells reduces B10 cells in HCV-
infected mice. The HCV-infected mice were subjected to pcCD19scFv-
IL-10R, pcCD19scFv, or pcIL-10R treatment. (A) On day 60, splenic B10
cells were determined by flow cytometry. (B) B10 cells in liver tissues
were assessed by immunofluorescence assay (200 ×). Scale bar:100 μm.
Smaller images on the sides were after × 3.3 magnification. (C) Splenic
Treg cells were determined by flow cytometry. Data in (A) and (C)
are shown as the mean ± SD (n = 3 mice per experiment). *p < 0.05,
**p < 0.01, ANOVA with Neuman–Keuls posthoc test. All data are rep-
resentative of at least three independent experiments with similar
results.
pcIL-10R groups were significantly higher than that in pcCD19scFv
and pcDNA groups, indicating that number of cytotoxic CD8+
T cells could be enhanced in pcCD19scFv-IL-10R and pcIL-10R
groups (Fig. 7A and B and Supporting information Fig. 7A and B).
We then examined the cytotoxicity of the splenocytes using
an LDH assay. The highest level of splenocyte cytotoxic activity
was observed in pcCD19scFv-IL-10R group (Fig. 7C). More impor-
tantly, at lower E:T ratios of 5:1, the splenocytes in pcCD19scFv-IL-
10R group showed more effective cytotoxic activity on target cells
compared with IL-10R group (Fig. 7C). These results indicated that
pcCD19scFv-IL-10R treatment increases the splenocyte cytotoxic-
ity against the HCV-infected hepatocytes. Together, our results
demonstrated that treatment with pcCD19scFv-IL-10R increases
CD8+ T-cell responses and cytotoxic activity in vivo.
Discussion
HCV is a major hepatotropic virus causing chronic hepatitis and
also a virus that directly modulate B- and T-cell function [21,
22]. The increased level of B10 cells in CHC patients highlights
Figure 6. Neutralizing IL-10 production by B cells has no effect on Th
polarization during HCV infection. The HCV-infected mice were sub-
jected to pcCD19scFv-IL-10R, pcCD19scFv, or pcIL-10R plasmid treat-
ment. On day 60, IFNγ+ Th1 (A), IL-4+ Th2 (B), and IL-17A+ Th17 (C)
cells were determined by flow cytometry. Data in (A)-(C) are shown as
the mean ± SD (n = 3 mice per experiment). NS, no significant (p > 0.05),
ANOVA with Neuman–Keuls posthoc test. All data are representative
of at least three independent experiments with similar results.
the immunomodulatory function of B10 cells during HCV infec-
tion [5]. In the present study, we found that HCV induces both
human and murine B cells to produce IL-10 in vitro (Fig. 1A–
D, 2A–E and Supporting information Fig. 1A and B). We also
found that HCV-induced murine B10 cells were enriched in CD19hi
and CD1dhiCD5+ cell populations (Fig. 1C, D, 2D, and E). This
finding was consistent with previous studies which demonstrated
that murine B10 cells are predominantly contained within a
CD1dhiCD5+ B cell subpopulation upon stimulation with LPS [23].
HCVcc does not infect PBMCs [24], but HCV virus and its viral
antigens can stimulate B cells. HCV core protein is reportedly
recognized by TLR2 [12, 25]. High concentrations of virion-free
soluble core protein are readily detected in the plasma of HCV-
infected individuals [26]. In the current study, HCV induced B10
cells mainly via TLR2 signaling pathway (Fig. 3A, B, and D). There-
fore, we speculated that soluble HCV core proteins can be released
from HCVcc-infected cells, which might be involved in induction
of B10 cells. Moreover, production of IL-10 in TLR4−/− B cells was
reduced compared with WT B cells after HCV stimulation, indicat-
ing that TLR4 signaling might be involved in IL-10 production in
B cells (Fig. 3A). It has been reported that HCVcc binds to B cells
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Figure 7. Neutralization of IL-10 production by B cells increases cyto-
toxic T-cell activity in HCV-infected mice. The HCV-infected mice were
treated with pcCD19scFv-IL-10R, pcCD19scFv, or pcIL-10R plasmids. On
day 60, perforin+CD8+ T cells from (A) spleen and (B) liver were deter-
mined by flow cytometry. Data are shown as the mean ± SD (n = 3
mice per experiment). **p < 0.01, ***p < 0.001, ANOVA with Neuman–
Keuls posthoc test. (C) pcCD19scFv-IL-10R treatment leads to increased
level of cytotoxic activity of the splenocytes. On day 60, murine spleno-
cytes were collected, stimulated with anti-CD3 mAb, anti-CD28, and
IL-2 for 5 days and were used as effector cells. Hepatocytes from HCV-
infected mice (HCV group) were used as target cells. The LDH release
assay were performed for cytotoxicity. Representative data are shown
as the mean ± SD (n = 6 mice per experiment). *p < 0.05, **p < 0.01,
vs pcDNA group; #p < 0.05, ##p < 0.01, vs IL-10R group; ANOVA with
Neuman–Keuls posthoc test. All data are from a single experiment rep-
resentative of three independent experiments.
via other receptors like CD81, SRBI, DC-specific IAM-3-grabbing
nonintegrin (DC-SIGN), and L-SIGN [27]. Whether TLR4 and
other receptors are involved in induction of HCV-induced B10
cells should be demonstrated in future work.
All mice (including the pcDNA group) subjected to plasmid
injection showed decreased Tregs, indicating that DNA plasmid
might act as an adjuvant and reduces Tregs during HCV infec-
tion (Fig. 5C and Supporting information Fig. 5B). These results
also demonstrated that experimental procedure alone affected the
immune response, and the effect of pcCD19scFv-IL-10R and pcIL-
10R treatment on Tregs was limited (Fig. 5C and Supporting infor-
mation Fig. 5B).
CD19-generated signals are critical for B10-cell development
[23, 28]. In the current study, pcCD19scFv treatment blocked
the CD19 signaling, resulting to reduce the B10 cells in HCV-
infected mice (Fig. 5A and B and Supporting information Fig.
5A). Moreover, IL-10 acts in an autocrine manner to regulate the
differentiation of B cells [29, 30]. CD19scFv-IL-10R and IL-10R
might block IL-10 to bind to the IL-10 receptor on B cells, resulting
in further reduction of B10 cells (Fig. 5A and B and Supporting
information Fig. 5A).
CD19scFv has no Fc fragment. Although CD19scFv binds to
CD19, it cannot mediate antibody-dependent cellular cytotoxicity
(ADCC) or other cytotoxic effects via Fc fragment. In our study,
the B10 cells even B cells were markedly reduced in liver tis-
sues in the mice subjected to pcCD19scFv treatment compared
with pcDNA + HCV group (Fig. 5B). Other studies show that per-
sistent virus infections are associated with B-cell dysregulations,
and CHC patients have the risk to develop mixed cryoglobuline-
mia which is associated with B-cell proliferative disorder and B-
cell non-Hodgkin’s lymphoma (B-NHL) [31–33]. We speculated
that CD19scFv might inhibit B-cell proliferative disorder caused
by chronic HCV infection. Whether the CD19 scFv inhibits of
B-cell proliferative disorder or directly depletes B cells should be
assessed in future work.
B10 cells reportedly skew CD4+ Th-cell differentiation and
suppress cytotoxic CD8+ T cells [34]. However, in this study,
blocking IL-10 production of B cells with pcCD19scFv-IL-10R
demonstrated its limited effects on Th polarization (Fig. 6A–C
and Supporting information Fig. 6A-C). Two factors might con-
tribute to these results: first, pcCD19scFv-IL-10R treatment only
partially neutralized IL-10 from B cells; and second, HCV-induced
B10 cells would be functionally heterogeneous resulting in the
limited effects on Th polarization. Nevertheless, pcCD19scFv-IL-
10R treatment markedly increased perforin production by CD8+
T cells and promoted the cytotoxicity of splenocytes against HCV-
infected cells (Fig. 7A–C and Supporting information Fig. 7A-7B),
demonstrating that neutralization of B cell-secreted IL-10 could
promote cytolytic activity of CD8+ T cells against HCV. However,
titers of HCV were not reduced in pcCD19scFv group, while IL-10
level and B10 cells were decreased in pcCD19scFv group compared
pcDNA control group (Fig. 4B and C and 5A). These indicated that
other mechanisms beyond B10-cell reduction or even IL-10 reduc-
tion might be involved in decreasing HCV titer in pcIL-10R and
pcCD19scFv-IL-10R groups.
There are some limitations in our current study. The mock
control of supernatants from noninfected Huh7.5.1 cells should
be used to exclude the effect of possible contaminates in the
HCVcc preparation. It is better to use anti-CD20 or anti-B220
antibody to detect B cells in the murine model to exclude the
possibility that the binding capacity of anti-CD19 antibody
influenced by CD19scFv. The levels of IL-10 and plasmid encoded
proteins should be measured at the same day in murine model
to rule out any confounding effects of proteins on production
or stability of plasmid encoded proteins. We did not measure
the inflammatory details in livers except HE analysis (Fig. 4E)
in the murine model. The alanine aminotransferase (ALT) levels
and more liver histology analysis should be done to evaluate
the inflammatory of liver after pcCD19scFv-IL-10R or pcIL-10R
treatment. Additionally, whether CD19scFv-IL10R strictly binds
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to B cells and whether it also neutralizes IL-10 independent of
binding to CD19 need to be verified. An IL-10 knockout (KO)
or even a B cell-specific IL-10 KO mouse model needs to be
employed to further clarify the roles of B10 cells during long-term
HCV infection. We will do these work in our future study.
Direct-acting antivirals have revolutionized HCV treatment,
proving to be effective treatment options for HCV-infected indi-
viduals [35, 36]. However, the emergence of drug resistant HCV
variants has been reported [37]. In our study, we showed that
blocking B10 cells by treatment with pcCD19scFv-IL-10R during
persistent HCV infection promotes protective immunity and alle-
viates liver damage caused by HCV infection by decreasing B10
cells and promoting the cytotoxicity of CD8+ T cells against HCV
in HCV-infected humanized mice. These results indicate that B10
cells can serve as a target for HCV therapy, and immunomodula-
tory agents blocking B10-cell activity might be potentially effective
for combination therapy against HCV infections.
Materials and methods
Blood samples
A sum of 14 healthy donors from Hubei Provincial Hospital of
Integrated Chinese & Western Medicine (Wuhan, China) were
provided informed consent before blood donation. PBMCs were
obtained by Ficoll density gradient centrifugation (Axis-Shield,
Dundee, Scotland). This study was approved by the ethics com-
mittee of the Wuhan University School of Basic Medical Science
(No.150001).
Animals
Animal protocols were approved by the Institutional Animal
Care and Use Committee of the Animal Laboratory Center of
Wuhan University (No. 2017077 and No. 2017095). WT C57BL/6,
TLR2−/−, and TLR4−/- mice were purchased from the Biomed-
ical Research Institute of Nanjing University (Nanjing, China).
ICRTg4R+ humanized mice expressing human CD81, OCLN, SRB1,
and CLDN1 genes in liver tissues, were bred on an ICR genetic
background and characterized by Beijing Vitalstar Biotechnology
Co., Ltd (Beijing, China). All mice were bred and maintained at the
university animal facility under standard specific-pathogen free
conditions.
Plasmids, virus, and cell culture
pcCD19scFv-IL-10R, pcIL-10R, and pcCD19scFv were constructed
as previously described [9]. Huh7.5.1 cells were cultured in com-
plete DMEM (Thermo Fisher Scientific, Waltham, MA, USA) with
10% fetal bovine serum (FBS, HyClone, Logan, USA). Expansion
of cell culture-derived HCV (HCVcc, genotype 2a, Japanese fulmi-
nant hepatitis 1, JFH1 isolate) was performed using Huh7.5.1
cells as described in our previous publication [38]. In brief,
Huh7.5.1 cells were infected with HCVcc (MOI of 1; 1 × 107
RNA copies/mL). The supernatants from infected cells were har-
vested after 5 days and filtered through a 0.22-μm filter, concen-
trated 100-fold using an Amicon Ultra-4 (Millipore, Burlington,
USA) at 4000 g for 45 min and aliquoted for storage at −80 °C.
Magnetic activated cell sorting (MACS)
B cells were purified and isolated from murine splenocytes
using CD19 positive MACS (Miltenyi Biotec, Bergisch Glad-
bach, Germany). Briefly, mouse splenocytes were incubated with
microbeads-conjugated monoclonal rat antimouse CD19 antibod-
ies at 4 °C for 15 min. After immobilization of all these cells with
a magnet, untouched CD19-cells were discharged. CD19+ B cells
were then flushed from the column.
Flow cytometry (FCM)
Flow cytometry analyses were performed according to the guide-
lines used for immunological studies [39]. To detect human B10
cells, PBMCs (2 × 106 cells/mL) were stimulated with HCVcc (1
× 106 RNA copies/mL) in medium containing IL-2 (30 U/mL;
Peprotech, Rocky Hill, NJ, USA) for 48 h. Brefeldin A (1000 ×)
was added 6 h before harvesting the cells. Samples were har-
vested and incubated with human Fc Receptor Blocking Solution
(Biolegend, San Diego, CA, USA) to block FcRs, followed by stain-
ing with FITC anti-CD19 (SJ25C1). Cells were then fixed with
fixation/permeabilization buffer (Biolegend). Permeabilized cells
were stained with anti-IL-10 (JES3-9D7) and isotype control APC
Rat IgG1, κ Isotype (RTK2071) antibodies. In the medium group,
PBMCs were cultured in the presence of IL-2 in DMEM supple-
mented with 10% FBS.
To detect murine B10 cells, splenic B cells (2 × 106 cells/mL)
were stimulated in vitro with various concentrations of HCVcc
in medium containing IL-2 for 0-72 h. Antimouse CD16/CD32
antibody (clone 93) was used to block FcRs. Samples were stained
with the following antibodies: FITC anti-CD19 (6D5), PerCP-Cy5.5
anti-mouse CD1d (CD1.1, Ly-38), Alexa Fluor 647 anti-CD5 (53-
7.3), PE anti-IL-10 antibody (JES5-16E3), or isotype control PE
Rat IgG2b, κ antibodies. In the medium group, the cells were
cultured in the presence of IL-2 in DMEM supplemented with 10%
FBS.
For the murine model of HCV infection, splenocytes iso-
lated from HCV-infected mice were directly stained with antibod-
ies. The following antibodies were used: APC-anti-CD3(17A2),
PE/Cy5/FITC-anti-CD4 (RM4-5), PerCP-Cy5.5-anti-CD8a (53-
6.7), PE-anti-IFN-γ (XMG1.2), PE-anti-IL-4 (11B11), PE-anti-IL-
17A (TC11-18H10.1), PE-anti-perforin (S16009A), and Alexa
Fluor 488-anti-Foxp3 (MF-14). All the antibodies were purchased
from Biolegend. Samples were measured using a BD FACSAriaTM
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III flow cytometer (BD Biosciences, San Jose, CA, USA) at the
Medical Structural Biology Research Center of Wuhan University.
Enzyme-linked immunosorbent assay (ELISA)
For IL-10 detection, murine splenic CD19+ B cells (1 × 106
cells/mL) were stimulated with HCVcc (1 × 106 RNA copies/mL)
in medium containing IL-2 for 0-72 h. IL-10 production in the
supernatant was detected by ELISA (Dakewe Biotech Co., Guang-
dong, China). To assess the signaling adaptors involved in IL-
10 production by B cells, B cells were pretreated with LY294002
(PI3K inhibitor, 20 μM; Selleck, Houston, TX, USA), LY2228820
(P38 inhibitor, 10 μM; MedChemExpress, Monmouth Junction,
NJ, USA), ST-2825 (MyD88 inhibitor, 10 μM; MedChemExpress),
curcumin (AP1 inhibitor, 10 μM; MedChemExpress), or BAY 11–
7082 (NF-κB inhibitor, 10 μM; Selleck) for 1 h before stimulation
with HCVcc.
For the murine model of HCV infection, mouse serum was
collected for IL-10 detection.
Immunoblot analysis
B cells (1 × 106 cells/mL) were stimulated with HCVcc (1 × 106
RNA copies/mL) in medium containing IL-2 for 0-12 h. The cells
were lysed in 250 μL of RIPA Lysis Buffer (Beyotime Biotech-
nology, Shanghai, China). Lysates were separated on a 5-10 %
SDS-polyacrylamide gel, transferred onto polyvinylidene difluo-
ride membranes (Millipore), and then probed with specific anti-
bodies. Bound antibodies were detected with HRP-conjugated sec-
ondary antibodies and visualized by chemiluminescence (Dalian
Meilun Biology Biotechnology Co., Ltd., Dalian, China). Semi-
quantification was performed by densitometry using the UVP
bioimaging system (UVP, Cambridge, UK). The following anti-
bodies were used: p-PI3K p85 (Tyr607), PI3 Kinase p110α, p-AKT
(Ser473), AKT (pan), p-NF-κB p65 (Ser 536), NF-κB p65, AP-1(p-
c-fos) (Ser32), and β-actin antibodies. p-PI3K p85 (Tyr607) was
purchased from Abcam (Cambridge, UK) other antibodies were
purchased from Cell Signaling Technology (Danvers, MA, USA).
In the murine model, mouse serum was collected 5 days after
plasmid injection. Serum protein levels of CD19scFv-IL-10R, sIL-
10Ra, and CD19scFv were detected by immunoblotting using anti-
IL-10R (R&D Systems, Minneapolis, MN, USA) or anti-His-Tag
antibody (Proteintech, Rosemont, IL, USA). Sixty days after HCV
infection, mouse liver tissue was homogenised and analyzed by
immunoblot analysis using anticore (Abcam,), anti-NS3 (Abcam),
and anti-GAPDH antibodies (ABclonal Technology, Woburn, MA,
USA).
Humanized murine model of persistent HCV infection
We developed the reported murine model for persistent HCV infec-
tion [16–18]. Briefly, 10-week-old ICRTg4R+ mice were randomly
divided into six groups (six mice/group). On day 0, mice were
intravenously (i.v.) injected with HCVcc (MOI of 1; 1 × 107 RNA
copies/mouse). Mice were injected intramuscularly (i.m.) weekly
with pcCD19scFv-IL-10R, pcIL-10R or pcCD19scFv (35 μg/100μL
of PBS per mouse) by electroporation with an Electric Square
Porator (TERESA, Shanghai, China) [9]. Electroporation was per-
formed using 6 × 1 Hz pulses of 60 V/cm, with 50 ms duration
and 1 s apart.
The mice were sacrificed by carbon dioxide anesthesia and
cervical dislocation on day 60. HCV RNA copies in serum were
determined by RT quantitative PCR (RT-qPCR). Serum IL-10 lev-
els were determined by ELISA. Frequencies of B10 cells and Tregs
in spleens, IFN-γ, IL-4, and IL-17A production by splenic CD4+
T cells, and perforin production by CD8+ T cells were analyzed
directly ex vivo by flow cytometry. Cytotoxicity of splenocytes
against HCV-infected hepatocytes was measured by LDH cytotox-
icity assay.
RT quantitative PCR (RT-qPCR)
HCV RNA in serum from HCVcc-infected mice was quantified using
a PCR-Fluorescence Quantification Kit for HCV RNA (DaAN Gene
Co., Ltd., Guangzhou, China). Briefly, HCV RNA from serum was
isolated by a column containing a special silicon membrane to
isolate RNA fragments. Isolated RNA samples were then subjected
to RT-qPCR assay using primers provided by the manufacturer.
Histopathology, immunohistochemistry (IHC), and
immunofluorescence
Liver tissues were fixed in 4% paraformaldehyde, embedded in
paraffin and sectioned (5 μm) for HE and Masson’s trichrome
staining. The immunohistochemistry (IHC) assay were performed
as described elsewhere [16, 40] using primary antibody anti-NS3
(Abcam) and peroxidase-labelled rabbit anti-mouse IgG (Service-
bio, Woburn, USA). Immunofluorescence staining was performed
as described previously [39]; frozen sections of liver tissue (4 μm)
were fixed and blocked, and then stained with anti-CD19 (Ser-
vicebio) and anti-IL-10 antibody (Absin Bioscience Inc., Shanghai,
China). Thereafter, nuclei were stained with DAPI (Servicebio).
Cytotoxicity assay
The CytoTox 96 LDH release assay (Promega, Madison, WI,
USA) was used to detect splenocyte cytotoxicity. Sixty days
after infection with HCV, murine splenocytes were collected,
stimulated with anti-CD3 mAb (5 μg/μL; Biolegend), anti-CD28
(2 μg/μL; Biolegend) and IL-2 (50 IU/mL) for 5 days and used as
effector cells. Hepatocytes from HCV-infected mice (HCV group)
were used as target cells (10 000 cells/well) and coincubated
with the splenocytes at E:T ratios of 1:1, 5:1, and 10:1. After
8 h of incubation, 50 μL supernatant from each well was mixed
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with 50 μL of the substrate at room temperature in the dark for
15-30 min. Absorbance of samples was then measured at 490 nm
to determine the LDH activity in the supernatants.
Quantification and statistical analysis
Data are presented as mean ± SD and analyzed by GraphPad Prism
V 5.00 for Windows (GraphPad Software, La Jolla, CA, USA). Sta-
tistical significance was determined by Student’s t-test or ANOVA
followed by Newman–Keuls posthoc test. p-values less than 0.05
were considered statistically significant.
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